• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

antibody-drug conjugates

Merck  Co headquarters
Biotech

Merck’s TROP2 ADC extends survival in pivotal cancer trial

Sac-TMT improved overall survival in a phase 3 cancer trial, delivering a second pivotal global win for the TROP2-directed antibody-drug conjugate.
Nick Paul Taylor Nov 20, 2026 11:20am
Photo of an ax atop a pile of three logs

Kyntra drops mid-stage ADC, adding to years of stumbles

Nov 17, 2026 10:40am
Boehringer biopharmaceutical manufacturing facility in Shanghai

Boehringer bags $7.4B Sino deal for 6 preclinical TCEs, ADCs

Nov 4, 2026 9:08am
topic report
National Breast Cancer Awareness Month pink ribbon

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

Oct 28, 2026 9:00am
ESMO 2026

From RAS rivalry to leaked readouts, ESMO brought the data drama

Oct 27, 2026 8:00am
GSK booth at ASCO 2026

GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3

Oct 27, 2026 3:28am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings